These were KEI comments to USTR regarding PhRMA’s efforts to target Malaysia as a Priority Foreign Country for issuing a compulsory license on sofosbuvir patents. Malaysia.14March2018.KEI.USTR.Special 301 March 14, 2018 The Honorable Robert Lighthizer United States Trade Representative Executive Office… Continue Reading
KEI submitted a post-hearing submission to the USTR for the Special 301 on behalf of itself and twelve other international NGOs and academic institutions condemning recent pressures on Colombia’s legal and regulatory measures to increase access to affordable medicines, including… Continue Reading
Bayh-Dole cases involving royalty free or march-in rights 1997 Cellpro case This was a strong case involving two competing medical devices, both invented on NIH grants, and a bad ending. The NIH rejection of the Cellpro march-in request led to… Continue Reading
KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading
More on 1498 here: https://www.keionline.org/cl/28usc1498 There is a discussion of compensation under 28 USC §1498 in Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies. UNDP and World Health Organization. 2005 (pages 18-21 in the UNDP edition, and… Continue Reading
The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading
2000 SPECIAL 301 REPORT United States Trade Representative Charlene Barshefsky today announced the results of the 2000 “Special 301” annual review which examined in detail the adequacy and effectiveness of intellectual property protection in over 70 countries. Ambassador Barshefsky also… Continue Reading
OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE Executive Office of the President Washington, D.C. 20508 For Immediate Release April 30, 1999 Contact: Jay Ziegler, Helaine Klasky, Amy Stilwell, (202) 395-3230 USTR ANNOUNCES RESULTS OF SPECIAL 301 ANNUAL REVIEW United States… Continue Reading
Public and Private Sector Funded Research for Fabry’s Disease KEI Research Note 2010:2 23 July 2010 Introduction Fabry’s disease is a rare genetic multisystemic disorder associated with progressive lipid accumulation and cell damage, leading to a variety of aliments, including… Continue Reading
Databases Delinkage Enforcement and Remedies to Infringement Events General Access to Knowledge Issues Government Funded Inventions Hepatitis Nuclear Proliferation Patent Policy Prizes to stimulate innovation Publications and Research Notes Timelines WTO LDC patent waiver Transparency Judge rejects USTR claim that… Continue Reading